<DOC>
	<DOCNO>NCT00849095</DOCNO>
	<brief_summary>Study No.001 Budesonide/Formoterol use ASthMA sponsor Agenzia Italiana del FArmaco ( Italian Drug Agency ) ( AIFA-ASMA-BF-001 ) The aim study verify whether asthma control low dos inhaled corticosteroid , thus need step therapy , equally control guideline recommend regular bid treatment long act beta agonist/inhaled corticosteroid ( ICS/LABA ) combination symptom drive use ICS/LABA combination absence maintenance therapy . The study design able evaluate non inferiority regular placebo plus prn inhale budesonide/formoterol ( experimental treatment ) versus regular , twice daily 160/4.5 mcg inhale budesonide/formoterol combination plus prn inhaled terbutaline ( guideline recommend treatment ) .</brief_summary>
	<brief_title>Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline Mild-Moderate Asthma</brief_title>
	<detailed_description>Asthma problem worldwide , estimate 300 million affect individuals.There evidence asthma prevalence increase last decades country , include Italy . Analyses cost asthma lead conclude burden disease depend extent exacerbation avoid since emergency treatment expensive regular treatment . Based solid evidence , international guideline recommend regular treatment low dose ICS mild persistent asthma treatment combination therapy [ low dose ICS plus long-acting beta2-agonists ( LABA ) ] patient asthma control low dos ICS alone . Recent study undermine axiom treatment ICS must regular achieve maintain asthma control , equivalent control obtain either prn use inhale combination short act beta2 agonist ( SABA ) ICS , short course 10 day high dose ICS start exacerbation . In moderate-severe asthma regularly treat inhaled ICS/LABA combination , symptom-driven use inhale ICS/LABA combination reliever superior symptom-driven use SABA LABA alone .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male female outpatient age 18 year 65 year Clinical diagnosis moderate persistent asthma least 6 month , accord GINA revise version 2006 guideline Postbronchodilator force expiratory volume ( FEV1 ) least 80 % predict Either positive methacholine challenge test ( PC20 FEV1 &lt; 4mg/ml PD20 FEV1 &lt; 0.8 mg ) positive response reversibility test last year Asthma either adequately control lowdose ( â‰¤500 mcg beclomethasone equivalent ) inhale corticosteroid ( ICS ) control bid inhale combination lowdose ICS/long act beta2 agonist ( LABA ) A cooperative attitude ability train correctly use dry powder inhalator complete diary card Written inform consent obtain Inability carry pulmonary function test Moderate severe asthma associate reduced lung function History nearfatal asthma and/or admission intensive care unit asthma 3 course oral corticosteroid hospitalization asthma previous year Diagnosis COPD define GOLD guideline Evidence severe asthma exacerbation symptomatic infection airways previous 8 week Current smoker recent ( less one year ) exsmokers , define smoke least 10 pack/years History current evidence heart failure , coronary artery disease , myocardial infarction , severe hypertension , cardiac arrhythmia Diabetes mellitis Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) previous six month Abnormal ECG Clinically significant unstable concurrent disease : uncontrolled hyperthyroidism , significant hepatic impairment , poorly control pulmonary disease ( tuberculosis , active mycotic infection lung ) , gastrointestinal ( e.g. , active peptic ulcer ) , neurological haematological autoimmune disease Malignancy Any chronic disease prognosis &lt; 2 year Pregnant lactating female able exclude pregnancy study period History alcohol drug abuse Patients treat monoamine oxidase inhibitor , tricyclic antidepressant betablockers regular use Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient Patients unlikely comply protocol unable understand nature , scope possible consequence study Patients receive investigational new drug within last 12 week Patients previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Adult</keyword>
	<keyword>Asthma</keyword>
	<keyword>Bronchodilator Agents</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Double-Blind Method</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ethanolamines</keyword>
	<keyword>Female</keyword>
	<keyword>Forced Expiratory Volume</keyword>
	<keyword>Humans</keyword>
	<keyword>Male</keyword>
	<keyword>Terbutaline</keyword>
</DOC>